What are the Implications of New Anti-Obesity Drugs for Racial Disparities?
This policy watch discusses some of the potential implications of the new anti-obesity drugs for racial equity.
View the Latest: Prescription Drugs
Filter
-
-
Over-the-Counter Oral Contraceptive Pills
Issue BriefOral contraceptives are the most commonly used method of reversible contraception in the U.S. In July 2023, the FDA approved Opill, the first daily oral contraceptive pill to become available over the counter (OTC) without a doctor’s prescription. This issue brief provides an overview of OTC oral contraceptives and laws and policies related to insurance coverage.
-
KFF Health Tracking Poll: MAHA and the Midterms
Poll FindingThis KFF Health Tracking Poll finds that the cost of health care is a more prominent focus for Make America Healthy Again (MAHA) voters than issues like food and vaccine policy. Four in ten MAHA voters (42%) choose lowering health costs as the most important health priority, outranking other MAHA priorities.
-
MAHA Health Concerns Resonate Broadly but Lag Behind Health Care Costs Even for MAHA Voters
News ReleaseChemical food additive and pesticide concerns associated with the Make America Health Again (MAHA) movement are shared broadly across the public. But when it comes to voters, health care costs are a higher priority and bigger motivator, even among MAHA supporters, a new KFF Health Tracking Poll finds.
-
Costly GLP-1 Drugs are Rarely Covered for Weight Loss by Marketplace Plans
News ReleaseAffordable Care Act (ACA) Marketplace plans rarely cover GLP-1 drugs approved solely for obesity treatment, according to a new KFF analysis of 2024 federal plan data. Wegovy, a drug that is approved for weight loss, is covered by just 1% of Marketplace prescription drug plans, compared to 82% of Marketplace prescription drug plans for Ozempic, which contains the same active ingredient as Wegovy (semaglutide) but is approved only for diabetes. When GLP-1 drugs are covered…
-
International Comparison of Health Systems
FeatureThis Health Policy 101 chapter explores the performance of the U.S. health system on a number of cost, outcomes, and quality measures by comparing it with those in similarly large and wealthy OECD nations. It highlights that despite significant spending, Americans have shorter life expectancies and encounter more barriers to health care, influenced by both the health system's structure and broader socioeconomic factors.
-
Medicare Part D Premiums Are Increasing for Many But Not All Stand-Alone Plans in 2025, Reflecting Effects of New Premium Stabilization Demonstration
Policy WatchThis policy watch examines monthly premiums for Medicare Part D stand-alone drug plans in 2025, as changes to the Part D benefit are being implemented in 2025, including a new $2,000 cap on out-of-pocket drug spending.
-
2024 Employer Health Benefits Chart Pack
FeatureThis slideshow captures key data from the 2024 KFF Employer Health Benefits Survey survey, providing a detailed look at trends in employer-sponsored health coverage, including premiums, employee contributions, cost-sharing, abortion coverage, offer rates, wellness programs, and other employer practices.
-
A Current Snapshot of the Medicare Part D Prescription Drug Benefit
Issue BriefThis brief provides an overview of the Medicare Part D prescription drug benefit, including current data on plan availability, enrollment, and spending and financing, and highlights changes made under the Inflation Reduction Act.
-
Chartpack — The Public’s Health Care Agenda for the New President and Congress
Poll FindingChartpack -- The Public's Health Care Agenda for the New President and Congress This chartpack provides the key findings from the survey of the public's attitudes regarding the health care agenda for President Obama and the new Congress in 2009. It assesses the relative priority placed on health care by the American public as part of addressing the economic recession and as a large scale reform issue. The public's priorities for health care reform and…